Personal profile

Research interests

Jinbin Xu is extensively experienced in biomedical imaging science, focusing on the development and characterization of probes for receptor and enzyme-based central nervous system (CNS) and oncology imaging using in vivo Positron Emission Tomography (PET) and in vitro quantitative autoradiography. Dr. Xu is an expert in postmortem rodent/nonhuman primate/human brain quantitative autoradiography and high throughput receptor-ligand binding assays. In addition, Dr. Xu developed a novel autoradiography procedure for measuring dopamine D2 and D3 receptor density ratios. This method has been effectively used with animal models of neurological disease and for human postmortem brain autoradiography. He also played a crucial role in validating the sigma-2 receptor as an imaging biomarker for cell proliferation and developing sigma-2 receptor antagonists against amyloid-beta oligomer toxicity in human neurons as a therapeutic agent in Alzheimer disease.


Jinbin Xu is currently leading a diverse team and conducting various innovative researches via modern technologies such as quantitative imaging, biochemistry, genetics, radiomics, and proteomics. In addition, Dr. Xu is interested in mentoring graduate students and postdoctoral researchers on research proects within the scope of the following programs.

Current research programs:

  1. Postmortem validation and characterization of a variety of biomarkers for disease progression imaging of Alzheimer’s disease, Parkinson disease, and other central nervous disorders;
  2. Dopamine functions and regulations in nigrostriatal neuron degeneration; and investigation of an agonist of D3 receptor as autophagy enhancing agent for degradation of alpha-synuclein aggregates;
  3. Evaluation and development of sigma-2 receptor antagonists against amyloid-beta oligomer toxicity in human neurons as a therapeutic agent in Alzheimer's disease;
  4. Inflammation and oxidative DNA damage involved in cancer, neurodegeneration, and cardiovascular disease;
  5. Developing cancer imaging and radiation therapy probes targeting different cellular regions: DNA, nucleus membrane, cell membrane, and cytosol.

Future Directions:

  1. Continuing current projects with advanced technologies of genomics and molecular biology: single nuclei sequencing and two-dimensional mass spectrum analysis;
  2. Systematically compare pathological and genetic alternations in dominantly inherited and sporadic Alzheimer’s diseases, as well as Parkinson disease dementia;
  3. Understanding the mechanism of the sigma-2 receptor as an anti-beta-amyloid target for treating Alzheimer’s disease;
  4. Developing and characterizing novel autophagy biomarkers and enhancing agents, and exploring their potential application for treating Alzheimer and Parkinson diseases, and other disorders;
  5. Development of cancer imaging and radiation therapy probes targeting cancer cells and stromal cells. 

Available to Mentor:

  • PhD/MSTP Students
  • Postdocs
  • Residents and Fellows


Dive into the research topics where Jinbin Xu is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or